tirzepatide pdufa Learn more about Zepbound® (tirzepatide) injection - Is compoundedtirzepatidegoing away how tirzepatide affects body weight The Significance of the Tirzepatide PDUFA Date in Transforming Treatment Landscapes

GLP-1 compoundtirzepatide The tirzepatide PDUFA date represents a critical juncture in the evolution of therapeutic options, particularly for type 2 diabetes mellitus (T2DM) and obesity. A PDUFA date, named after the Prescription Drug User Fee Act, is the target deadline set by the U.S. Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA). These dates are pivotal, signaling potential approvals that can dramatically reshape patient care.

Tirzepatide, a novel dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, has garnered significant attention due to its efficacy in clinical trials2025年6月21日—FDA Approved: Yes(First approved November 8, 2023) Brand name: Zepbound Generic name: tirzepatide Dosage form: Injection Company: Eli Lilly and Company. Developed by Eli Lilly and Company, tirzepatide is administered via once-weekly subcutaneous injections. Its initial foray into the pharmaceutical landscape was marked by the FDA's approval of Mounjaro (tirzepatide) on May 13, 2022, for adults with type 2 diabetes. This approval was a significant event, as Mounjaro was the first dual GIP and GLP-1 receptor agonist to receive FDA approval for this indicationTirzepatide Subcutaneous Solution - accessdata.fda.gov. The PDUFA date for Mounjaro's initial approval was a key milestone, underscoring the rigorous FDA review process.

Beyond diabetes management, tirzepatide has demonstrated remarkable results in weight loss.2025年9月16日—Orforglipron is designed to mimic the appetite-suppressing GLP-1 hormone targeted by Lilly's blockbuster injectiontirzepatidesold under the ... Clinical studies, such as the SURMOUNT-1 trial, have shown that tirzepatide can lead to substantial reductions in body weight, positioning it as a promising treatment for individuals struggling with overweight and obesity. This led to the subsequent FDA approval of Zepbound (tirzepatide) on November 8, 2023Learn more about Zepbound® (tirzepatide) injection, a weight loss medication for adults with obesity and also for moderate-to-severe obstructive sleep apnea .... Zepbound is specifically indicated for chronic weight management in adults with obesity or with overweight and at least one weight-related comorbidity. The FDA approval of Zepbound (tirzepatide) marked another significant achievement for the drug, opening up new avenues for treating obesity.2022年5月13日—The US FDA has approved a priority NDA for Eli Lilly and Co.'s Mounjaro (tirzepatide), an injectable treatment for adults with type 2 diabetes (T2D). The PDUFA date for Zepbound's approval was closely watched by the medical community and patients alike.

The FDA Approved: Yes status for both Mounjaro and Zepbound highlights the successful navigation through the regulatory pathways. The PDUFA date associated with these approvals served as a deadline for the FDA to make a decision on the drug's safety and efficacy for its intended uses.

However, the rise of tirzepatide has also brought complexities, particularly concerning compounded tirzepatide.GLP-1 Pipeline Update: May 2025 While tirzepatide is the active ingredient in FDA-approved medications like Mounjaro and Zepbound, compounded tirzepatide is not FDA-approved and can pose significant safety risksZepbound® (tirzepatide) Injection for Adults with Obesity or OSA. The FDA has issued warnings against companies illegally selling unapproved drugs containing tirzepatide, semaglutide, or retatrutide, often falsely labeled "for research." This has led to discussions and concerns about whether compounded tirzepatide is still available and the potential consequences of its use. The FDA has also clarified policies for compounders amidst the national GLP-1 shortage, emphasizing the importance of using FDA-approved products.作者：AM Jastreboff·2022·被引用次数：3376—Tirzepatideis a once-weekly subcutaneous injectable peptide (approved by the Food and Drug Administration [FDA] for type 2 diabetes) ... The general sentiment from regulatory bodies is that Mounjaro and Zepbound are indicated for the treatment of serious diseases; they are not approved for – and should not be used for – cosmetic weight loss.

Another significant development in the tirzepatide narrative is its recent FDA approval as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. This approval, stemming from studies like the SURMOUNT-OSA trial, highlights the multifaceted benefits of tirzepatideIs Compounded Tirzepatide Safe?. In this context, Zepbound was about five times more effective than placebo in reducing breathing disruptions, a crucial finding for a condition that significantly impacts health and quality of life. Tirzepatide is the first targeted treatment for OSA, addressing obesity's underlying impact on disease pathophysiology. The FDA approval of Zepbound (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity underscores its expanding therapeutic role.

The FDA's Concerns with Unapproved GLP-1 Drugs Used for various purposes, including weight management, further emphasize the regulatory body's stance on ensuring patient safety and the integrity of approved medications. The FDA's commitment to reviewing these applications within established timelines, often between 10-12 months after submission, is crucial for bringing safe and effective treatments to market. For example, the PDUFA date for zuranolone was Aug. 5, 2023, illustrating the timeline for other drug reviews, while the PDUFA date is typically: 10-12 months after the submission of a New Drug ApplicationThis draft guidance, when finalized, will represent the current thinking of the Food and Drug. Administration (FDA, or the Agency) on this topic..

Looking ahead, tirzepatide continues to be a subject of ongoing research. Eli Lilly has withdrawn an application to the FDA for tirzepatide use in heart failure, specifically for HFpEF, demonstrating the dynamic nature of drug development and regulatory review. The development of other related medications, such as orforglipron, a pill designed to mimic the appetite-suppressing GLP-1 hormone targeted by injectable tirzepatide, also indicates a robust pipeline in this therapeutic area. Understanding how tirzepatide affects body weight remains a key focus of ongoing studies, aiming to further optimize its use and explore its full potential2023年7月13日—The PDUFA action date for zuranolone isAug. 5, 2023. If the FDA approves the drug, it would become Sage Therapeutics' second treatment for PPD.. The journey from a tirzepatide application to an FDA approval, marked by a specific PDUFA date, signifies a thorough evaluation to ensure the drug meets the stringent standards for public health.